ENvue Medical Inc

ENvue Medical Inc(FEED)股票分析

$1.030

-0.713 (-69.25%)收盘时

Loading chart…
最高
3.420
开盘
3.340
成交量加权均价
1.76
成交量
1.22M
市值
—
最低
0.840
成交额
2.16M
企业价值/息税折旧摊销前利润(TTM)
0.00

ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract.

AI 分析 of ENvue Medical Inc (FEED)

卖出

ENvue Medical, Inc. (FEED) is not a good buy right now due to its extremely low price of $1.03, a staggering year-to-date change of -96.50%, and an RSI of 7.252 indicating oversold conditions. The company has also reported a gross margin of -111.30% in Q2 2026, highlighting severe profitability issues. The main risk is its recent performance, with a 5-day change of -75.93%, indicating continued downward pressure on the stock.

估值指标

ENvue Medical Inc(FEED)当前预期市盈率为 0.00,5 年平均预期市盈率为 -0.00。

预期市盈率

严重高估
5 年均值 P/E
-0.00
当前P/E
0.00
高估
-0.00
低估
-0.00

预期 EV/EBITDA

严重低估
5 年均值 EV/EBITDA
0.00
当前EV/EBITDA
0.00
高估
0.00
低估
0.00

预期市销率

严重低估
5 年均值 P/S
0.88
当前P/S
0.00
高估
1.04
低估
0.72

事件时间线

2026-10-29 (ET)

08:00:00

ENvue Medical Begins UroShield Production in the U.S.

2026-10-26 (ET)

08:00:00

ENvue Medical CEO Emphasizes Profitability Goals and Market Expansion

2026-09-15 (ET)

13:00:00

ENvue Medical's Nasdaq Listing Request Denied

2026-09-09 (ET)

09:30:00

ENvue Medical Resumes Commercial Shipments of PainShield

2026-08-10 (ET)

16:30:00

ENvue Medical Files $50M Mixed Securities Shelf

资讯

FEED 常见问题 —— 由 Alphio AI 解答

ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. It operates in the Healthcare sector.

ENvue Medical, Inc. (FEED) is not a good buy right now due to its extremely low price of $1.03, a staggering year-to-date change of -96.50%, and an RSI of 7.252 indicating oversold conditions. The company has also reported a gross margin of -111.30% in Q2 2026, highlighting severe profitability issues. The main risk is its recent performance, with a 5-day change of -75.93%, indicating continued downward pressure on the stock.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易